Biogen Inc (BIIB)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$165.68

Buy

$181.50

arrow-up$1.60 (+0.93%)

Prices updated at 13 Dec 2025, 00:57 EST

Prices minimum 15 mins delay

Prices in USD

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Ms. Caroline D. Dorsa

CEO

Mr. Christopher A. Viehbacher

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

7,605

Head office

225 Binney Street

Cambridge

United States

02142

+1 617 679-2000

IR@biogen.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Sean Godbout Vice President, Chief Accounting Officer and Global Corporate Controller	-
Ms. Caroline D. Dorsa Chairman of the Board	0.23m
Dr. Eric K. Rowinsky,M.D. Independent Director	0.16m
Mr. William A. Hawkins, III Independent Director	0.17m
Dr. Stephen A. Sherwin, M.D. Independent Director	0.14m
Mr. Christopher A. Viehbacher Director, President and Chief Executive Officer	1.60m
Ms. Susan H. Alexander Executive Vice President and Chief Legal Officer	0.95m
Dr. Ginger Gregory, PhD Executive Vice President and Chief Human Resources Officer	-
Dr. Maria C. Freire, PhD Independent Director	0.14m
Professor Menelas Pangalos, PhD Independent Director	-
Ms. Robin C. Kramer Chief Financial Officer	-
Dr. Priya Singhal, M.D.,M.P.H. Executive Vice President and Head of Development	0.82m
Mr. Jesus B. Mantas Independent Director	0.17m
Mr. Monish D. Patolawala Independent Director	0.14m
Dr. Jane Grogan, PhD Executive Vice President, Head of Research	-
Mr. Rachid Izzar Executive Vice President, Global Product Strategy and Commercialization	-
Ms. Nicole Murphy Executive Vice President, Pharmaceutical Operations and Technology	0.76m
Mr. Adam Keeney, PhD Executive Vice President and Head of Corporate Development	-
Ms. Susan K. Langer Independent Director	0.13m
Dr. Lloyd B. Minor, M.D. Independent Director	0.03m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	17,290,651
Vanguard Group Inc. ( Junked)	16,677,806
PRIMECAP Management Company	14,954,697
BlackRock Inc	14,763,952
Vanguard PrimeCap Fund	8,452,780

Director dealings

Date chevron-l-regular chevron-r-regular	Action
06 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
09 Dec 2024	-
05 Nov 2024	-
05 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
30 Aug 2024	-
30 Aug 2024	-
03 Sep 2024	-
30 Aug 2024	-
21 Jun 2024	-
21 Jun 2024	-
21 Jun 2024	-
21 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.